Comerica Bank Has $50.76 Million Stake in Amgen Inc. $AMGN

Key Points

• Comerica Bank trimmed its Amgen position by 6.3%, selling 10,395 shares and now holding 155,074 shares valued at $50.76 million in its latest 13F filing.
• Amgen beat quarterly expectations with $5.29 EPS (vs. $4.76 consensus) and $9.87B revenue, set FY2026 EPS guidance of 21.600–23.000, and announced a quarterly dividend of $2.52 (annualized $10.08, ~2.9% yield).
• Institutional investors own about 76.5% of the stock—big funds like Vanguard and Capital World Investors increased holdings—while the analyst consensus is a Hold with a $356.62 target amid mixed recent ratings.

Comerica Bank lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 155,074 shares of the medical research company's stock after selling 10,395 shares during the period. Comerica Bank's holdings in Amgen were worth $50,757,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Capital World Investors raised its holdings in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after purchasing an additional 961,975 shares in the last quarter. National Bank of Canada FI raised its holdings in shares of Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock valued at $346,076,000 after purchasing an additional 863,216 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Amgen by 71.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock valued at $383,254,000 after purchasing an additional 567,400 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Amgen by 91.6% during the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company's stock valued at $221,607,000 after purchasing an additional 375,463 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $344.55 on Monday. The firm's 50-day moving average is $360.74 and its 200-day moving average is $339.77. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market cap of $185.95 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 3.60 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the firm posted $5.31 EPS. The business's revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.16 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen's payout ratio is presently 70.84%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported completion of an early Phase 1/2 MTAP‑null cancer combination study — a clinical milestone that can de‑risk a development program and supports longer‑term oncology pipeline value. Company Study Completion
• Positive Sentiment: Guggenheim nudged its price target on AMGN to $351 (maintaining a Neutral rating), which signals modest analyst upside versus the stock’s trading range and can provide short‑term support. Guggenheim PT Update
• Neutral Sentiment: Amgen confirmed it will report Q1 2026 results after the market close on April 30 and will host a webcast — an obvious near‑term volatility driver as investors adjust positions into the print. Q1 Webcast
• Neutral Sentiment: Legislation (H.R. 8203) expanding workforce and treatment funding for substance use disorders was introduced; Amgen is listed among relevant healthcare companies — this is a longer‑horizon policy item that could modestly affect labor/training dynamics but is unlikely to move the stock immediately. H.R.8203 Bill
• Negative Sentiment: Pre‑earnings previews from Zacks and Yahoo Finance suggest AMGN may report a decline in Q1 earnings (reducing the odds of an earnings beat), which increases downside risk into the report. Earnings Preview
• Negative Sentiment: Insiders sold roughly US$4.1M of Amgen stock over the past year — sizable insider selling can be perceived as a cautionary signal by some investors. Insider Selling
• Neutral Sentiment: Amgen announced the planned retirement of EVP & Chief Technology Officer David M. Reese effective June 30, 2026, with a strategic leadership realignment — a governance event to watch, but presented as orderly and planned. CTO Retirement

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on AMGN shares. Jefferies Financial Group started coverage on shares of Amgen in a report on Tuesday, March 10th. They set a "hold" rating and a $350.00 price target on the stock. Freedom Capital downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. Sanford C. Bernstein downgraded shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target on the stock. in a report on Tuesday, January 20th. TD Cowen restated a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Mizuho raised their price target on shares of Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and a consensus target price of $356.62.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.